End-of-day quote
Taiwan S.E.
23:00:00 09/05/2024 BST
|
5-day change
|
1st Jan Change
|
69.9
TWD
|
-1.13%
|
|
+2.79%
|
-6.55%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
4,642
|
4,057
|
4,566
|
4,685
|
4,549
|
4,260
|
Enterprise Value (EV)
1 |
4,642
|
4,057
|
4,566
|
4,685
|
4,549
|
4,260
|
P/E ratio
|
44.5
x
|
64.1
x
|
52.6
x
|
51.5
x
|
748
x
|
58.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.14
x
|
-
|
-
|
2.12
x
|
2.59
x
|
2.03
x
|
EV / Revenue
|
2.14
x
|
-
|
-
|
2.12
x
|
2.59
x
|
2.03
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
14.6
x
|
-
|
-
|
1,015
x
|
-50.8
x
|
10.5
x
|
FCF Yield
|
6.83%
|
-
|
-
|
0.1%
|
-1.97%
|
9.48%
|
Price to Book
|
2.27
x
|
-
|
-
|
2.26
x
|
-
|
2.18
x
|
Nbr of stocks (in thousands)
|
57,670
|
59,756
|
60,236
|
60,687
|
60,820
|
60,942
|
Reference price
2 |
80.50
|
67.90
|
75.80
|
77.20
|
74.80
|
69.90
|
Announcement Date
|
15/03/20
|
21/03/21
|
29/03/22
|
15/03/23
|
15/03/24
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
2,173
|
-
|
-
|
2,211
|
1,756
|
2,098
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
156.3
|
-
|
-
|
131.4
|
-13.34
|
91
|
Operating Margin
|
7.19%
|
-
|
-
|
5.94%
|
-0.76%
|
4.34%
|
Earnings before Tax (EBT)
1 |
134.6
|
-
|
-
|
86.48
|
-31.88
|
91
|
Net income
1 |
106.3
|
62.43
|
87.41
|
91.02
|
6.209
|
72
|
Net margin
|
4.89%
|
-
|
-
|
4.12%
|
0.35%
|
3.43%
|
EPS
2 |
1.810
|
1.060
|
1.440
|
1.500
|
0.1000
|
1.190
|
Free Cash Flow
1 |
317.1
|
-
|
-
|
4.617
|
-89.64
|
404
|
FCF margin
|
14.59%
|
-
|
-
|
0.21%
|
-5.11%
|
19.26%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
298.39%
|
-
|
-
|
5.07%
|
-
|
561.11%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/03/20
|
21/03/21
|
29/03/22
|
15/03/23
|
15/03/24
|
-
|
Fiscal Period: December |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
564.8
|
596.8
|
468.5
|
495
|
533
|
590
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
22.33
|
45.2
|
-3.452
|
13
|
28
|
50
|
Operating Margin
|
-
|
3.95%
|
7.57%
|
-0.74%
|
2.63%
|
5.25%
|
8.47%
|
Earnings before Tax (EBT)
1 |
-
|
10.17
|
21.49
|
-13.1
|
13
|
28
|
50
|
Net income
1 |
39.25
|
10.3
|
27.69
|
-5.039
|
10
|
22
|
40
|
Net margin
|
-
|
1.82%
|
4.64%
|
-1.08%
|
2.02%
|
4.13%
|
6.78%
|
EPS
2 |
0.6400
|
0.1700
|
0.4500
|
-0.0800
|
0.1700
|
0.3600
|
0.6600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/08/22
|
10/11/22
|
15/03/23
|
10/05/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
317
|
-
|
-
|
4.62
|
-89.6
|
404
|
ROE (net income / shareholders' equity)
|
5.27%
|
-
|
-
|
4.4%
|
0.31%
|
3.72%
|
ROA (Net income/ Total Assets)
|
2.36%
|
-
|
-
|
1.91%
|
0.12%
|
1.53%
|
Assets
1 |
4,497
|
-
|
-
|
4,773
|
5,140
|
4,706
|
Book Value Per Share
2 |
35.50
|
-
|
-
|
34.10
|
-
|
32.00
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
88.5
|
-
|
-
|
138
|
293
|
50
|
Capex / Sales
|
4.07%
|
-
|
-
|
6.23%
|
16.69%
|
2.38%
|
Announcement Date
|
15/03/20
|
21/03/21
|
29/03/22
|
15/03/23
|
15/03/24
|
-
|
Last Close Price
69.9
TWD Average target price
80
TWD Spread / Average Target +14.45% Consensus |
1st Jan change
|
Capi.
|
---|
| -6.55% | 131M | | -1.29% | 12.64B | | -0.47% | 8.46B | | +22.61% | 5.27B | | -2.03% | 4.49B | | -53.56% | 3.11B | | +19.30% | 2.87B | | +33.07% | 2.31B | | -8.42% | 2.23B | | -3.55% | 1.89B |
Diagnostic & Testing Substances
|